NIOWAVE, INC. (NASDAQ: APVO) discloses 98,522 shares and $8 warrants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
NIOWAVE, INC., a ten percent owner of Aptevo Therapeutics Inc., filed an initial ownership report on Form 3. The filing shows direct ownership of 98,522 shares of Common Stock. It also lists a warrant to buy 53,201 shares of Common Stock at an exercise price of $8.00 per share, expiring on May 25, 2031.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
NIOWAVE, INC.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrant (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Warrant (right to buy) — 53,201 shares (Direct, null);
Common Stock — 98,522 shares (Direct, null)
Footnotes (1)
Key Figures
Common shares owned: 98,522 shares
Warrant underlying shares: 53,201 shares
Warrant exercise price: $8.00 per share
+2 more
5 metrics
Common shares owned
98,522 shares
Directly owned Common Stock reported on Form 3
Warrant underlying shares
53,201 shares
Underlying Common Stock for reported warrant
Warrant exercise price
$8.00 per share
Exercise price of warrant to buy Common Stock
Warrant expiration
May 25, 2031
Expiration date of warrant position
Holding entries
2 entries
One Common Stock position and one warrant position
Key Terms
Form 3, ten percent owner, Warrant (right to buy), exercise price, +1 more
5 terms
Form 3 regulatory
"filed an initial ownership report on Form 3"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
ten percent owner regulatory
"NIOWAVE, INC., a ten percent owner of Aptevo Therapeutics Inc."
Warrant (right to buy) financial
"Warrant (right to buy) with underlying Common Stock shares"
exercise price financial
"a warrant to buy 53,201 shares at an exercise price of $8.00"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"the warrant expires on May 25, 2031"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What does NIOWAVE, INC.'s Form 3 filing for APVO show?
The Form 3 shows NIOWAVE, INC. as a ten percent owner of Aptevo Therapeutics Inc., holding 98,522 Common shares and a warrant to purchase 53,201 additional shares at $8.00 per share, expiring on May 25, 2031.
What is the exercise price and expiration date of NIOWAVE's APVO warrant?
The reported warrant held by NIOWAVE, INC. on Aptevo Therapeutics has an exercise price of $8.00 per share. According to the Form 3, the warrant expires on May 25, 2031, defining the period during which it can be exercised.
Is the NIOWAVE, INC. Form 3 for APVO a record of a new trade?
The Form 3 is an initial ownership report, not a trade confirmation. It lists NIOWAVE, INC.’s existing holdings in Aptevo Therapeutics, including 98,522 Common shares and a warrant for 53,201 shares, rather than reporting a new purchase or sale.